Frederick, MD (PressExposure) July 28, 2008 -- “Certolizumab pegol is a representative example of the new generation of drugs that hold promise for the management of rheumatoid arthritis,” said Dr. Nathan Wei, one of the invited attendees.

Dr. Wei states, “It is now possible- in fact almost probable- if we get to a patient with rheumatoid arthritis soon enough- that we can get them into remission. Certolizumab is a major step because it can be used less frequently, once every four weeks as opposed to every two weeks for some of the other drugs in this class, and it is less painful than other preparations of this type.”

“A downside of these unique medications- the TNF-alpha group- has been that the injection is painful and they have to be given fairly frequently. I believe the trend will be towards less frequent injections.”

“So far, the biologic drugs we do have namely Humira, Enbrel, and Remicade, are excellent drugs. And they will continue to be the benchmark for newer medicines as they come along. A cure for rheumatoid arthritis will be available in our lifetime,” emphatically adds Dr Wei.

About Arthritis & Osteoporosis Center of Maryland

Dr. Wei is a board-certified rheumatologist and is director of the research program at the Arthritis and Osteoporosis Center of Maryland, a nationally recognized arthritis research center, located in Frederick, Maryland.

Press Release Source: http://PressExposure.com/PR/Arthritis_|_Osteoporosis_Center_of_Maryland.html